Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants.
Introduction
Streptococcus pneumoniae causes severe infectious diseases such as meningitis, bacteremia and pneumonia, and common illnesses including sinusitis and otitis media [1, 2] . Three licensed pneumococcal conjugated vaccines (PCVs) contain polysaccharides of 7, 10, or 13 pneumococcal serotypes out of the more than 90 known [3] . Although these PCVs have significantly decreased the burden of invasive pneumococcal disease [4, 5] , the incidence of non-vaccine pneumococcal serotypes has increased [6] .
The use of conserved pneumococcal protein antigens in nextgeneration vaccines could potentially provide protection against S. pneumoniae regardless of the capsular serotypes [7] . Two investigational vaccine formulations containing pneumolysin toxoid (dPly) and pneumococcal histidine-triad protein D (PhtD) have been shown to be well-tolerated and immunogenic when administered as a single dose to 2-4 year-old children in The Gambia [8] , or as a 2+1 schedule to European toddlers [9] .
Currently, in infant vaccination programs, several vaccines are co-administered. This increases the risk of post-immunization febrile reactions and febrile seizures [10, 11] and in consequence may require use of antipyretics, medical visits, or hospitalization. New antigens or vaccines should not increase reactogenicity when they are combined or co-administered.
This study assessed the safety, reactogenicity and immunogenicity of 2 investigational vaccine formulations, containing either 10 or 30 mg of dPly and PhtD each and the serotypespecific polysaccharide conjugates of the pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix, GSK, Belgium), when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa, GSK, Belgium) to healthy infants. The primary objectives of the study were to compare the pneumococcal protein-containing vaccines to PHiD-CV with respect to the occurrence of febrile reactions (rectal temperature >40.0°C) with causal relationship to primary vaccination, using pre-defined non-inferiority criteria.
Methods

Study design and participants
This phase II, randomized, multicenter, observer-blind, controlled study was conducted in the Czech Republic, Germany, Poland and Sweden between 24 September 2010 and 1 October 2012.
Inclusion/exclusion criteria are detailed in Supplementary Material, Text S1. Healthy infants aged 6-14 weeks at the time of first vaccination were randomized (1:1:1:1) to receive PHiD-CV/ dPly/PhtD-10, PHiD-CV/dPly/PhtD-30, PHiD-CV, or the 13-valent PCV (PCV13; Prevenar 13 TM , Pfizer). Treatment allocation at the investigator site was performed using an internet central randomization system. Sub-randomization to generate serology subsets comprising ±50% of participants from each group for the analyses of opsonophagocytic activity (OPA) and of immune responses to co-administered vaccine components was done at GSK using SAS.
Due to differences in physical appearance of the study vaccines, the study was conducted in an observer-blind manner, meaning that vaccine recipients, persons evaluating study endpoints, and laboratory staff were unaware of the vaccine administered. Authorized medical personnel with no further role in the study prepared and administered the vaccines.
The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. Written informed consent was obtained from the infants' parents or legally accepted representatives before study enrollment. The study protocol, amendments, and informed consent forms were reviewed and approved by national/regional Independent Ethics Committees. The study is registered at ClinicalTrials.gov (NCT01204658) and available at http://www.gsk-clinicalstudyregister.com (ID: 113994).
Study vaccines
The 2 investigational formulations contained, in addition to the conjugated polysaccharides of PHiD-CV, dPly and PhtD either at 10 lg of each (PHiD-CV/dPly/PhtD-10) or at 30 lg of each (PHiD-CV/dPly/PhtD-30) [8, 12, 13] . Control groups received PHiD-CV or PCV13. Vaccines were administered at 6-14 weeks, 3 and 4 months of age (primary doses), and 12-15 months of age (booster dose).
All groups received DTPa-HBV-IPV/Hib concomitantly at each vaccination visit. Vaccines were administered intramuscularly into the right (pneumococcal vaccines) or left thigh (DTPa-HBV-IPV/Hib).
Outcomes
The first co-primary objective was to compare PHiD-CV/dPly/ PhtD-10 to PHiD-CV with respect to the occurrence of febrile reactions (fever >40.0°C) causally related to primary vaccination. The second co-primary objective compared PHiD-CV/dPly/PhtD-30 to PHiD-CV in the same manner. Non-inferiority of PHiD-CV/dPly/ PhtD formulations to PHiD-CV was to be demonstrated if an increase in the percentage of infants with rectally measured temperature >40.0°C causally related to primary vaccination above 5% plus half the incidence in the PHiD-CV group (null hypothesis) was ruled out with a 1-sided p-value < 0.05. The objectives were assessed sequentially.
The first confirmatory secondary objective compared the PHiD-CV/dPly/PhtD formulations; superiority of one formulation over the other was to be demonstrated post-primary vaccination, if the upper limits of the 95% confidence intervals for the geometric mean concentration (GMC) ratio (10 mg/30 mg or 30 mg/10 mg) for anti-Ply and anti-PhtD antibodies were <1. Other secondary objectives assessed immune responses to pneumococcal proteins, pneumococcal serotype-specific polysaccharides, protein D, and DTPa-HBV-IPV/Hib, as well as safety and reactogenicity in all study groups.
Safety and reactogenicity assessment
Solicited local and general symptoms occurring within 7 days after each vaccination, and unsolicited adverse events (AEs) occurring within 31 days after each vaccination were recorded on diary cards. Large swelling reactions were solicited post-booster, and serious adverse events (SAEs) throughout the entire study (Text S2).
AE intensity was graded on a scale from 1 (mild) to 3 (severe). All solicited local reactions were considered causally related to vaccinations. The causality of all the other AEs was assessed by the investigator.
Immunogenicity assessment
Blood samples were collected pre-vaccination, 1 month postdose 3, pre-booster (8-11 months post-primary vaccination) and 1 month post-booster (Fig. S1 ). Sera were stored at À20°C until analysis. Assays are detailed in Table S1 . Statistical analyses are described in Text S2.
Results
Demographics
Out of the 576 enrolled infants, 575 were included in the total vaccinated cohort of primary vaccination, and 537 in the immuno-genicity according-to-protocol cohort; the booster total vaccinated cohort counted 564 toddlers, of which 527 were included in the immunogenicity according-to-protocol cohort (Fig. 1) . Demographic characteristics were similar between all groups (Table S2) .
Safety and reactogenicity
No fever >40.0°C was reported during the primary vaccination for any of the 4 groups, thus non-inferiority criteria were met, as the null hypothesis was ruled out with a 1-sided p-value of 0.003.
Post-primary vaccination, the most frequently reported local symptom at the pneumococcal vaccine injection site was redness in all groups (after 33.6%-38.1% of vaccine doses); post-booster vaccination, redness in the PHiD-CV/dPly/PhtD-10 (47.9%) and PHiD-CV (41.0%) groups, and pain in the PHiD-CV/dPly/PhtD-30 (45.7%) and PCV13 (44.3%) groups were most common. Local grade 3 symptom incidence remained under 6% following each dose in all groups. Symptoms at pneumococcal vaccines or DTPa-HBV-IPV/ Hib injection sites had similar incidences across all groups ( Fig. 2A and B) . Irritability was the most frequently reported general symptom for both primary (after 55.0%-56.6% of doses) and booster (59.0%-66.0%) vaccination in all groups (Fig. 2C) . No apparent increases in the incidences of solicited local and general symptoms were observed following consecutive doses of either Fig. 1 . Flow chart for study participants with reasons for elimination from according-to-protocol analyses. *One infant was enrolled, but no study vaccine doses were administered. N, number of children in each group; ATP, according-to-protocol; SAE, serious adverse event; AE, adverse event.
PHiD-CV/dPly/PhtD-10 or PHiD-CV/dPly/PhtD-30 during the primary vaccination period, but there was a trend towards higher incidences following booster vaccination (Fig. 2) . Most solicited symptoms were reported within the first 4 days of each vaccination (Fig. S2) .
Post-booster dose, no large swelling reactions at the injection site of the investigational vaccines were reported, while 6 cases were reported for other vaccines (4 for DTPa-HBV-IPB/Hib, 1 for PHiD-CV and 1 for PCV13).
During primary vaccination, at least 1 unsolicited symptom was reported after 16.9% of PHiD-CV/dPly/PhtD-10 and 21.4% of PHiD-CV/dPly/PhtD-30 doses, and after 20.1% of PHiD-CV and 20.0% of PCV13 doses (Table S3 ). The most frequently reported unsolicited symptoms were conjunctivitis, bronchitis, nasopharyngitis and rhinitis. At least 1 unsolicited symptom assessed by the investigator to be causally related to vaccination was reported after 0.2% and 0.5% of doses for PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/ PhtD-30 groups, 0.9% for PHiD-CV, and 0.2% for the PCV13 group.
Post-booster vaccination, at least 1 unsolicited symptom was reported for 27.8% and 18.6% of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 recipients, for 19.3% of PHiD-CV, and 24.3% of PCV13 recipients. Vaccination-related unsolicited symptoms were reported for none of the PHiD-CV/dPly/PhtD vaccinees, for 1.4% of PHiD-CV, and 0.7% of PCV13 vaccinees.
SAEs were reported for 56 children during the primary vaccination course (12 in PHiD-CV/dPly/PhtD-10 group, 9 in PHiD-CV/ dPly/PhtD-30 group, 21 in PHiD-CV group, and 14 in PCV13 group), and for 4 in the post-booster period (1 in PHiD-CV/dPly/PhtD-10 group and 3 in PCV13 group). No fatal events were reported. One hypotonic-hyporesponsive episode on the day of the first PHiD-CV dose was considered causally related to vaccination; the event resolved without sequelae after 6 days. Four SAEs not causally related to vaccination did not resolve by study end (2 cases of psychomotor retardation in PHiD-CV/dPly/PhtD-10 and PHiD-CV groups each, 1 type I diabetes mellitus in the PHiD-CV/dPly/ PhtD-30 group, and 1 thermal burn in the PCV13 group). Fig. 2 . Incidence of solicited local symptoms during the 7-day period following administration of pneumococcal vaccine (A) and DTPa-HBV-IPV/Hib vaccine (B) and incidence of solicited general symptoms (C), post-each dose and overall/dose for the first 3 doses (total vaccinated cohort). Note: Error bars indicate 95% confidence intervals. Grade 3 solicited symptoms were defined as ''crying when limb was moved" (pain); surface diameter >30 mm (redness/swelling); ''rectal temperature >40°C or tympanic/oral/ axillary temperature >39.5°C" (fever); ''crying that could not be comforted or which prevented normal activities" (irritability/fussiness); ''preventing normal activity" (drowsiness); and ''not eating at all" (loss of appetite). 
Immunogenicity
Superiority of PHiD-CV/dPly/PhtD-30 over PHiD-CV/dPly/PhtD-10 in terms of post-dose 3 antibody concentrations against Ply and against PhtD was demonstrated (Table 1 ). Higher anti-Ply and antiPhtD antibody geometric mean concentrations (GMCs) were observed following vaccination with PHiD-CV/dPly/PhtD-30 than with the PHiD-CV/dPly/PhtD-10 formulation.
Pneumococcal proteins
At all timepoints, all children in the PHiD-CV/dPly/PhtD groups were seropositive for Ply and PhtD, whereas in the control groups, not all were seropositive for PhtD during the booster phase ( Table 2 ). In both PHiD-CV/dPly/PhtD groups, anti-Ply antibody GMCs increased from pre-to post-primary vaccination, remained higher than baseline levels up to booster vaccination, and mounted again post-booster dose. In control groups, antibody GMCs declined from baseline to post-primary vaccination and tended to increase again at the subsequent timepoints, although values remained below the baseline. For PhtD, antibody GMCs increased 1 month post-primary vaccination only in PHiD-CV/dPly/PhtD groups. In all groups, pre-booster vaccination, anti-PhtD antibody GMCs tended to be lower than baseline values, and in control groups lower values than post-primary vaccination were observed. Following booster dose, anti-PhtD antibody GMCs increased in both PHiD-CV/dPly/PhtD groups, while they remained below baseline in control groups (Table 2) . At any timepoint, higher GMCs for Ply and PhtD antibodies were observed in the PHiD-CV/dPly/PhtD groups than in control groups as a consequence of immune response in the PHiD-CV/dPly/PhtD groups and decreased antibody level in the control groups.
Pneumococcal serotypes and protein D
One month post-primary vaccination, for 8 out of the 10 common serotypes (except 6B and 23F), at least 98.5% of infants in the PHiD-CV/dPly/PhtD groups, and at least 97.7% and 96.2% in the PHiD-CV and PCV13 groups had antibody concentrations ! 0.2 lg/mL (Table S4) . For serotypes 19A, 6A, and 3, the percentages of infants with antibody concentrations ! 0.2 lg/mL were at least 96.2% in the PCV13 group, while in the 3 PHiD-CV groups, the percentages ranged between 46.3-46.9% for serotype 19A, 31.8-33.8% for 6A, and 10.8-13.6% for serotype 3.
In all groups, for each PHiD-CV serotype, antibody GMCs were higher post-primary and post-booster vaccination compared to baseline. Pre-booster, for each PHiD-CV serotype, antibody GMCs had decreased but remained above baseline levels, except for 6B in PHiD-CV groups, for which an increasing trend in antibody GMCs over time was observed (Table 3) . For serotypes 19A and 6A, an increase in antibody GMCs across timepoints was evident post-booster vaccination, for all PHiD-CV groups. In the PCV13 group, antibody GMCs increased post-primary and post-booster vaccination for serotypes 19A, 6A and 3 (Table 3) .
One month post-primary vaccination, for each of the 10 PHiD-CV serotypes, at least 88.9% and 91.1% of infants in PHiD-CV/ dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 groups had OPA titers !8, except for serotype 1 (66.7% and 57.9%, respectively), while this percentage was !87.7% in the PHiD-CV group and !88.9% in the PCV13 group, except for serotype 1 (61.5% and 83.9% respectively) (Table S5) .
Increases in OPA titers were observed for each PHiD-CV serotype following primary and booster doses in the PHiD-CV/dPly/ PhtD groups, as well as in the control groups. For serotype 6A, an increase in OPA titers post-booster dose with respect to primary vaccination was observed in all PHiD-CV groups. There was no apparent increase in OPA titers for serotype 3 in PHiD-CV groups, following subsequent vaccine doses (Table 4) . Table 2 Percentage of children with anti-Ply antibody concentrations ! 12 EL.U/mL and anti-PhtD antibody concentrations ! 17 EL.U/mL, and GMCs for anti-Ply and anti-PhtD antibodies, by timepoint (according-to-protocol cohort for immunogenicity).
Timepoint
PHiD-CV/dPly/PhtD-10 N, number of children with available results;%, percentage of children with antibody concentration higher or equal to the assay cut-off; GMC, geometric mean concentration; 95% CI, 95% confidence interval; EL.U, ELISA Units; ELISA, enzyme-linked immunosorbent assay; Pre-pri, pre-primary vaccination; Post-pri, 1 month post-primary vaccination; Pre-bst, pre-booster vaccination; Post-bst, 1 month post-booster-vaccination.
The percentage of infants with anti-protein D antibody concentrations ! 100 ELISA Units (EL.U)/mL increased from 12 to 19% prevaccination to at least 93.4% in the PHiD-CV groups and 40.9% in the PCV13 group post-primary vaccination. Pre-booster dose, these percentages ranged between 95.4 and 97.7% for groups receiving protein D-containing formulations, and decreased to 28.7% for the PCV13 group (Table S4) . anti-PD antibody GMC values in the 3 PHiD-CV groups increased following primary and booster vaccination, and were higher than those in the PCV13 group at all post-vaccination timepoints (Table 3) .
DTPa-HBV-IPV/Hib
Immune responses to the co-administered DTPa-HBV-IPV/Hib vaccine did not seem to differ across the 4 groups in terms of seropositivity rates or antibody levels, except for anti-tetanus Table 3 GMCs of anti-pneumococcal serotype-specific antibodies and anti-protein D antibodies, by timepoint (according-to-protocol cohort for immunogenicity). GMC, geometric mean concentration; N, number of children with available results; 95% CI, 95% confidence interval; Pre-pri, pre-primary vaccination; Post-pri, 1 month postprimary vaccination; Pre-bst, pre-booster vaccination; Post-bst, 1 month post-booster-vaccination; PD, protein D.
post-booster antibody GMC, which was lower in the PCV13 group than in the 3 PHiD-CV groups (Table S6 ).
Discussion
This is the first study assessing the safety and reactogenicity of 2 investigational vaccine formulations combining pneumococcal proteins with the 10 conjugated PHiD-CV polysaccharides administered according to a 3+1 schedule in infants 6-14 weeks of age at first vaccination.
In the context of pediatric vaccination, the occurrence of fever post-vaccination is a major concern for both parents and physicians [14] . The current study demonstrated that the addition of Ply and PhtD to the PHiD-CV formulation does not significantly increase incidences of post-vaccination fever >40.0°C compared to the licensed PHiD-CV, when co-administered with DTPa-HBV-IPV/Hib, which is a vaccine commonly included in pediatric immunization programs.
The reactogenicity profile of both PHiD-CV/dPly/PhtD formulations appeared to be similar to that of PHiD-CV. No apparent increased reactogenicity was observed after consecutive primary doses of the vaccines, while post-booster dose, incidences of local and general solicited symptoms seemed to be higher than those observed for primary vaccination. Incidences of unsolicited AEs appeared similar within the 3 PHiD-CV groups, and in line with previous reports on PHiD-CV co-administration with DTPa-HBV-IPV/Hib [15] . No fatal SAEs were reported in this study.
The induction of immune responses against Ply and PhtD by both investigational PHiD-CV/dPly/PhtD vaccines post primary vaccination seemed to be dose-dependent, with a higher response for the 30 mg formulation. This result complements previous studies assessing immune response induced by the 2 formulations against pneumococcal proteins in toddlers [9] and is in agreement with observations made in adults for other vaccines containing different doses of PhtD [16, 17] or dPly [18] . Pre-vaccination levels of anti-Ply and anti-PhtD antibodies in infants in control groups declined post-primary vaccination, likely due to the waning of maternal antibodies [19] [20] [21] . In both PHiD-CV/dPly/PhtD groups, one month post-primary vaccination, anti-Ply antibody GMCs increased compared to baseline and anti-PhtD antibody GMCs remained at least at pre-vaccination levels. The levels remained elevated 8 months post-dose 3 in PHiD-CV/dPly/PhtD vaccinees, while in control groups, they stayed below baseline at all timepoints, but followed different kinetics for each pneumococcal protein. A strong booster effect for Ply and PhtD antibodies was observed in the PHiD-CV/dPly/PhtD groups, especially following vaccination with PHiD-CV/dPly/PhtD-30. A similar observation was made in another infant study in the Gambia [22] . However, no correlates of protection in terms of magnitude of immune [23] [24] [25] [26] [27] [28] [29] , no effect of immunization with pneumococcal proteins on nasopharyngeal colonization was observed in the Gambian infants [22] . Another study has been ongoing to determine an effect on clinical disease endpoints such as AOM (ClinicalTrials.gov, NCT01545375).
Immune responses against the 10 PHiD-CV serotypes following administration of PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 were in the same ranges as those induced by the PHiD-CV vaccine. Addition of dPly and PhtD in quantities of either 10 or 30 lg each to the PHiD-CV polysaccharides did not appear to impact immune responses to vaccine serotypes.
We did not observe any interference in the immune response induced by DTPa-HBV-IPV/Hib when co-administered with PHiD-CV/dPly/PhtD vaccines. Immune responses against DTPa-HBV-IPV/Hib components did not seem to differ between the 3 PHiD-CV groups and were in line with previous results for coadministration with PHiD-CV [30] . This result, together with the safety assessment, suggests that both PHiD-CV/dPly/PhtD formulations can be co-administered with DTPa-HBV-IPV/Hib in infants.
The study has several strengths. High compliance rates with the protocol-defined procedures, including vaccination schedules, were observed, which supports the validity of safety and immunogenicity analyses. The study was designed to demonstrate 2 confirmatory objectives. Study limitations include the fact that, for the pneumococcal proteins, immunogenicity assessment was carried out by measuring antibody levels, for which the correlate of protection has not yet been established [31] . Although functional assays for pneumococcal protein antibodies may be better suited to characterize immune response, they were not available at the time of the analysis. No statistical comparisons between the 2 comparator vaccines were carried out, and OPA testing was performed in a limited subset of participants; therefore, comparison of the 2 licensed PCVs and OPA results should be interpreted with caution, bearing also in mind that the clinical relevance of the difference in immunogenicity profiles of these vaccines remains unknown and that evidence has grown on the comparability of their effect on pneumococcal diseases [32] . Lastly, anti-Ply and anti-PhtD antibody concentrations were determined through an assay not calibrated for values expressed in lg/mL, so a comparison with data reported in SI units is not possible.
Conclusions
PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 formulations co-administered with DTPa-HBV-IPV/Hib according to a 3+1 schedule during the first two years of life have shown a similar reactogenicity profile as the licensed PHiD-CV in terms of incidence of febrile reactions causally related to primary vaccination. Immune responses to vaccine pneumococcal serotypes and to coadministered DTPa-HBV-IPV/Hib vaccine antigens elicited in PHiD-CV/dPly/PhtD groups did not appear altered in comparison to those in the PHiD-CV group. Both formulations had a clinically acceptable profile with regard to tolerability and immunogenicity, comparable to PHiD-CV. 
